SCHEMBL4871213

SCHEMBL4871213

COC(=O)c1cc(I)cc(OC)c1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.56
POLB P06746 3/20 0.56
HSD17B10 Q99714 3/20 0.51
USP2 O75604 1/20 0.51
ALDH1A1 P00352 5/20 0.48
GAA P10253 5/20 0.48
HPGD P15428 3/20 0.47
NPSR1 Q6W5P4 2/20 0.44
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43
MAPK1 P28482 2/20 0.41
KMT2A Q03164 1/20 0.41
HTT P42858 1/20 0.41
MAPT P10636 2/20 0.41
NPC1 O15118 1/20 0.41
ABL1 P00519 1/20 0.41
PKM P14618 1/20 0.41
RECQL P46063 1/20 0.41
BLM P54132 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1530644 0.84 KDM4E (0.45) KDM4EPOLBHSD17B10USP2ALDH1A1
SCHEMBL7828568 0.84 PKM (0.49) KDM4EPOLBHSD17B10ALDH1A1HPGD
SCHEMBL9134970 0.82 KDM4E (0.47) KDM4EPOLBHSD17B10USP2ALDH1A1
SCHEMBL4878432 0.82 KDM4E (0.44) KDM4EPOLBHSD17B10USP2ALDH1A1
SCHEMBL30810326 0.82 KDM4E (0.44) KDM4EPOLBHSD17B10USP2ALDH1A1
SCHEMBL7354740 0.82 DRD2 (0.40) KDM4EPOLBHSD17B10USP2ALDH1A1
SCHEMBL27091758 0.82 KDM4E (0.47) KDM4EPOLBHSD17B10USP2ALDH1A1
SCHEMBL8364052 0.82 HTT (0.47) KDM4EPOLBALDH1A1GAAHPGD
SCHEMBL4870888 0.81 GALK1 (0.49) KDM4EPOLBHSD17B10USP2ALDH1A1
SCHEMBL27201894 0.81 KDM4E (0.46) KDM4EPOLBHSD17B10USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-A2 COMT INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-09-06 EP disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition F. HOFFMANN-LA ROCHE AG (CH) 2005-06-23 US disclosed
US-5446147-A Imaging agent TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 1995-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition COMT, MAOB, TPH1 KDM4E 1075/4885POLB 999/4885HSD17B10 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.